StockNews.com Initiates Coverage on RedHill Biopharma (NASDAQ:RDHL)

StockNews.com began coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research report sent to investors on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

RedHill Biopharma Trading Up 1.0 %

NASDAQ RDHL opened at $2.00 on Thursday. RedHill Biopharma has a one year low of $1.72 and a one year high of $20.28. The business’s fifty day moving average is $2.48 and its 200-day moving average is $5.11.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC acquired a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned about 0.40% of RedHill Biopharma as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 7.20% of the company’s stock.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.